Menu

Tamiflu Reviewed Again

The controversial antiviral drug earns better marks in the most recent analysis of the evidence. 

Jan 30, 2015
Kerry Grens

WIKIMEDIA, ANDREW WALESIn recent years, independent researchers have called into question governments’ big purchases of the antiviral drug Tamiflu, given that some analyses have not found considerable benefit from taking the medication. A new study of the available data, published in The Lancet yesterday (January 29), found Tamiflu to be somewhat more effective in reducing hospitalizations than earlier reports, although side effects remain.

In the latest study, led by Arnold Monto of the University of Michigan School of Public Health, patients with influenza who took Tamiflu had a reduced risk of needing antibiotics or being admitted to the hospital, but also had a higher risk of nausea and vomiting. “A study like this can’t on its own say whether it is worthwhile to trade off the reduction in the length of symptoms against the risk of nausea and vomiting,” Kevin Conway, a statistician at the Open University, told The Guardian.

Peter Doshi, an epidemiologist at the University of Maryland School of Pharmacy who participated in previous reviews of Tamiflu—and who advocated for the release of more data to be made available for independent reviewers—told ScienceInsider: “There are no new data presented here on complications or hospitalizations that we did not already know of.” Doshi said the difference in conclusions on Tamiflu’s benefits comes from how the data were interpreted—for instance, whether pneumonia diagnoses were consistent. He also told ScienceInsider that Roche, which makes Tamiflu, helped fund this latest study, indirectly.

Peter Openshaw, the director of the Centre for Respiratory Infection at Imperial College London, told The Daily Mail that “as a full review of the published and unpublished data, it leaves the conclusion unaltered that oseltamivir [Tamiflu] reduces symptom duration by about a day while causing nausea and vomiting in a minority of recipients. Oseltamivir is not a perfect drug but does what you might expect of an antiviral given relatively late in the course of an acute infection and after the illness has already become established.”

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.